Small cell glioblastoma multiforme: a case series and clinicopathological update
暂无分享,去创建一个
[1] R. Anghel,et al. Small cell glioblastoma: A glioblastoma subtype with an unexpected response , 2019, Medicina Moderna - Modern Medicine.
[2] C. Brennan,et al. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma , 2019, Journal of Neuro-Oncology.
[3] H. Takeuchi,et al. Clinicopathologic features of small cell glioblastomas , 2016, Journal of Neuro-Oncology.
[4] D. Tran,et al. Clinical Outcomes of Small Cell Glioblastoma or Glioblastoma With Oligodendroglioma Component Treated With Radiation Therapy and Temozolomide , 2014 .
[5] R. Vernhout,et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.
[6] K. Aldape,et al. Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma , 2004, Cancer.